Background: Chronic kidney disease (CKD) is a prevalent and debilitating condition, often compounded by the presence of type 2 diabetes. Elevated urinary albumin excretion is a hallmark of renal dysfunction, posing a significant risk to individuals with CKD. Dapagliflozin, the sodium-glucose co-transporter 2 inhibitor, has revealed promise in managing glycemic control in type 2 diabetes and demonstrating potential renoprotective effects. This study aims to investigate the impact of dapagliflozin on urinary albumin excretion in individuals having CKD, both with and without concurrent type 2 diabetes. Aim: The primary objective is to assess whether dapagliflozin administration can lead to a significant reduction in urinary albumin excretion in individuals with CKD. Additionally, the study aims to explore potential variations in treatment response between individuals with and without type 2 diabetes. Methods: A randomized controlled trial involving participants with diagnosed CKD, stratified into subgroups based on the occurrence or absence of type 2 diabetes, was conducted. Participants were administered dapagliflozin or a placebo for a specified duration. Urinary albumin excretion was measured at baseline, throughout treatment, and at the study’s conclusion. Clinical and biochemical parameters were also monitored to assess safety and overall renal function. Results: The outcomes had provided insights into the effect of dapagliflozin on urinary albumin excretion in individuals with CKD, elucidating potential differences in treatment response between those with and without type 2 diabetes. Statistical analyses were employed to determine the significance of observed changes. Conclusion: The results from that research contributed valuable information regarding the potential renoprotective effects of dapagliflozin in individuals with CKD. The differential impact on urinary albumin excretion in the presence or absence of type 2 diabetes was crucial for tailoring treatment strategies. That research covered way for personalized therapeutic interventions aimed at mitigating renal complications in that vulnerable population.
Keywords: Chronic kidney disease, type 2 diabetes, dapagliflozin, sodium-glucose co-transporter 2 inhibitor, urinary albumin excretion, renoprotective effects, randomized controlled trial.